Tina Marriott - Sep 29, 2022 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
President and COO
Signature
/s/ Nathan Hatfield, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Sep 29, 2022
Transactions value $
-$156,789
Form type
4
Date filed
10/3/2022, 07:32 PM
Previous filing
Aug 17, 2022
Next filing
Oct 28, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Options Exercise $17K +16K +7.8% $1.06* 221K Sep 29, 2022 Direct F1
transaction RXRX Class A Common Stock Sale -$173K -15.9K -7.21% $10.86 205K Sep 29, 2022 Direct F1, F2
transaction RXRX Class A Common Stock Sale -$738 -64 -0.03% $11.53 205K Sep 29, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Stock Option (Right to Buy) Options Exercise $0 -16K -2.59% $0.00 602K Sep 29, 2022 Class A Common Stock 16K $1.06 Direct F1, F3
holding RXRX Stock Option (Right to Buy) 159K Sep 29, 2022 Class A Common Stock 0 $11.40 Direct F4
holding RXRX Stock Option (Right to Buy) 4.78K Sep 29, 2022 Class A Common Stock 0 $11.40 Direct
holding RXRX Stock Option (Right to Buy) 150K Sep 29, 2022 Class A Common Stock 0 $2.47 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person.
F2 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.52 to $11.47 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F3 Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date.
F4 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F5 One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date.